174 related articles for article (PubMed ID: 36029326)
1. Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.
Gao F; Zhang T; Liu H; Li W; Liu X; Qiu L; Li L; Zhou S; Qian Z; Dong S; Zhao S; Wang X; Zhang H
Ann Hematol; 2022 Nov; 101(11):2383-2392. PubMed ID: 36029326
[TBL] [Abstract][Full Text] [Related]
2. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
[TBL] [Abstract][Full Text] [Related]
3. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
Casulo C; Dixon JG; Le-Rademacher J; Hoster E; Hochster HS; Hiddemann W; Marcus R; Kimby E; Herold M; Sebban C; Gyan E; Foon K; Nielsen T; Vitolo U; Salles GA; Shi Q; Flowers CR
Blood; 2022 Mar; 139(11):1684-1693. PubMed ID: 34614146
[TBL] [Abstract][Full Text] [Related]
4. Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.
Liu L; Yu X; Li Z; He X; Zha J; Lin Z; Hong Y; Zheng H; Lai Q; Ding K; Jia X; Fu G; Yu H; Yang H; Li Z; Young KH; Xu B
J Hematol Oncol; 2022 Aug; 15(1):115. PubMed ID: 35996180
[TBL] [Abstract][Full Text] [Related]
5. Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
Muntañola A; Mozas P; Mercadal S; Huguet M; Bobillo S; Bastos-Oreiro M; Jiménez-Ubieto A; Rovira J; Rivero A; Tolosa C; Luizaga L; de Villambrosia SG; Novelli S; Caballero D; Salar A; Alonso-Álvarez S; Magnano L; Gutiérrez NC; Sancho JM; López-Guillermo A;
Br J Haematol; 2023 Feb; 200(3):306-314. PubMed ID: 36261137
[TBL] [Abstract][Full Text] [Related]
6. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors JM; Gascoyne RD; Hiddemann W; Unterhalt M; Weinstock DM; Weigert O
Blood; 2016 Aug; 128(8):1112-20. PubMed ID: 27418643
[TBL] [Abstract][Full Text] [Related]
7. Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
Tobin JWD; Keane C; Gunawardana J; Mollee P; Birch S; Hoang T; Lee J; Li L; Huang L; Murigneux V; Fink JL; Matigian N; Vari F; Francis S; Kridel R; Weigert O; Haebe S; Jurinovic V; Klapper W; Steidl C; Sehn LH; Law SC; Wykes MN; Gandhi MK
J Clin Oncol; 2019 Dec; 37(34):3300-3309. PubMed ID: 31461379
[TBL] [Abstract][Full Text] [Related]
8. Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome.
Bitansky G; Avigdor A; Vasilev E; Zlotnick M; Ribakovsky E; Benjamini O; Nagler A; Kedmi M
Leuk Lymphoma; 2020 Nov; 61(11):2645-2651. PubMed ID: 32643497
[TBL] [Abstract][Full Text] [Related]
9. EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment.
Szumera-CieĆkiewicz A; Poleszczuk J; Paszkiewicz-Kozik E; Rymkiewicz G; SokÓŁ K; Borysiuk A; Kotarska M; Owczarek D; Kawecka M; Pytlak B; Walewski J; Prochorec-Sobieszek M
Anticancer Res; 2020 Dec; 40(12):6685-6697. PubMed ID: 33288562
[TBL] [Abstract][Full Text] [Related]
10. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract][Full Text] [Related]
11. Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.
Gao F; Liu H; Meng X; Liu J; Wang J; Yu J; Liu X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Golchehre Z; Chavoshzadeh Z; He J; Zhang H; Wang X
Br J Haematol; 2023 Sep; 202(6):1151-1164. PubMed ID: 37455019
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study.
Fernández-Miranda I; Pedrosa L; Llanos M; Franco FF; Gómez S; Martín-Acosta P; García-Arroyo FR; Gumá J; Horcajo B; Ballesteros AK; Gálvez L; Martínez N; Marín M; Sequero S; Navarro M; Yanguas-Casás N; Calvo V; Rueda-Domínguez A; Provencio M; Sánchez-Beato M
Clin Cancer Res; 2023 Jan; 29(1):209-220. PubMed ID: 36269794
[TBL] [Abstract][Full Text] [Related]
13. Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months.
Yoon SE; Cho J; Kim WS; Kim SJ
J Cancer; 2021; 12(9):2488-2497. PubMed ID: 33854610
[No Abstract] [Full Text] [Related]
14. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).
Moccia AA; Schär S; Hayoz S; Pirosa MC; Taverna C; Novak U; Kimby E; Ghielmini M; Zucca E
Br J Haematol; 2021 Mar; 192(6):1031-1034. PubMed ID: 32805081
[TBL] [Abstract][Full Text] [Related]
15. External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse.
Boyne DJ; Chua N; Owen C; Joe-Uzuegbu O; Shakir H; Gogna P; Jarada TN; Brenner DR; Elia-Pacitti J; Ewara EM; Cheung WY
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e277-e285. PubMed ID: 37331847
[TBL] [Abstract][Full Text] [Related]
16. Follicular Lymphoma in China: Systematic Evaluation of Follicular Lymphoma Prognostic Models.
Li Y; Zhang Y; Wang W; Wei C; Zhao D; Zhang W
Cancer Manag Res; 2022; 14():1385-1393. PubMed ID: 35422658
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of POD24 in peripheral T-cell lymphoma.
Chen H; Ma R; Zhang Q; Lu F; Ma Y; Zhou J; Cao J; Qi K; Yan Z; Sang W; Zhu F; Sun H; Li D; Li Z; Cheng H; Xu K; Chen W
Hematology; 2024 Dec; 29(1):2304483. PubMed ID: 38251872
[TBL] [Abstract][Full Text] [Related]
18. The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma.
Hu J; Gao F; Zhao J; Song W; Wang Y; Zheng Y; Wang L; Han W; Ma L; Wang J; Bai M; Guan T; Xi Y; Zhang H; Qiu L; Su L
Front Oncol; 2023; 13():1090610. PubMed ID: 37427106
[TBL] [Abstract][Full Text] [Related]
19. How I treat early-relapsing follicular lymphoma.
Casulo C; Barr PM
Blood; 2019 Apr; 133(14):1540-1547. PubMed ID: 30700421
[TBL] [Abstract][Full Text] [Related]
20. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.
Freeman CL; Kridel R; Moccia AA; Savage KJ; Villa DR; Scott DW; Gerrie AS; Ferguson D; Cafferty F; Slack GW; Farinha P; Skinnider B; Connors JM; Sehn LH
Blood; 2019 Aug; 134(9):761-764. PubMed ID: 31300404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
